We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Advertisement

Pivotal Phase II Study of Venetoclax Met Primary Endpoint

News   Aug 14, 2015

 
Pivotal Phase II Study of Venetoclax Met Primary Endpoint
 
 
Advertisement
 

RELATED ARTICLES

Data Shows Pfizer-BioNTech COVID-19 Vaccine Provides Protection From First Dose

News

An independent analysis conducted by Public Health England (PHE) in the UK demonstrates that the Pfizer-BioNTech COVID-19 vaccine BNT162b2 provides protection against infection and asymptomatic disease after the first dose.

READ MORE

HER2 Breast Cancer Cells Adopt Strategy To Resist Immunotherapy

News

Findings from a study published in Nature Communications reveal how cancer cells escape death by lymphocytes through the disruption of interferon-gamma signaling.

READ MORE

Team Develops Glioma-Targeted Anticancer Drug

News

Glioblastoma multiforme is a common and aggressive form of primary brain tumor that is particularly hard to treat. However, researchers now report a new glioma-targeted nano-therapeutic that will only address tumor cells offering increased effectiveness and reduced side effects.

READ MORE

 

Like what you just read? You can find similar content on the communities below.

Drug Discovery

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE